An additional line of therapy with pegylated interferon and ribavirin after rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia and indolent non-Hodgkin's lymphoma previously treated with interferon

Blood Transfusion

Volumn 10, Issue 1, 2012, Pages 101-103

  Mauro, Endri ^a   Pedata, Mariangela ^b   Ermacora, Anna ^b   Mazzaro, Cesare ^b  

^a CREMONA HOSPITAL   (Italy)

^b Pordenone General Hospital   (Italy)

Author keywords

Non Hodgkin's lymphoma; Pegylated interferon; Rituximab; Type II mixed cryoglobulinaemia

Indexed keywords

IMMUNOGLOBULIN; PEGINTERFERON; RIBAVIRIN; RITUXIMAB;

AGED; ARTHRALGIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRYOGLOBULINEMIA; DRUG MEGADOSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHODGKIN LYMPHOMA; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PURPURA; REMISSION; SKIN ULCER;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; LYMPHOMA, NON-HODGKIN; REMISSION INDUCTION; RIBAVIRIN;

EID: 84855753263     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2011.0006-11     Document Type: Article

References (11)

1. Zignego AL, Giannini C, Ferri C. Hepatitis C virus related lymphoproliferative disorders: an overview. World J Gastroenterol 2007; 13: 2467-78. (Pubitemid 46929503)
2. Saadoun D, Delluc A, Piette JC, Cacoub P. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008; 20: 23-8. (Pubitemid 351339428)
3. Donada C, Crucitti A, Donadon V, et al. Interferon alfa and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 1998; 92: 2983-4. (Pubitemid 28469122)
4. Zaja F, Russo D, Fuga G, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999; 84: 1157-8. (Pubitemid 30016593)
5. Lamprecht P, Lerin-Lonzano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinemic vasculitis. Ann Rheum Dis 2003; 62: 1230-3. (Pubitemid 37500635)
6. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 10: 3827-34. (Pubitemid 36857853)
7. Saaodoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus associated mixed cryoglobulinemia vasculitis: a long term follow-up study. Arthritis Rheum 2006; 54: 3696-706. (Pubitemid 44737183)
8. Terrier B, Saadoun D, Sène D, et al. Efficacy and tolerability of rituximab with or without pegylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis, a long term follow-up study of thirty two patients. Arthritis Rheum 2009; 60: 2531-40.
9. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus related mixed cryoglobulinemia and severe liver disease. Blood 2010; 116: 335-42.
10. Dammacco F, Tucci FA, Laulaetta G, et al. Pegylated interferon-alfa, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116: 343-53.
11. Saadoun D, Rigon MR, Sene D, et al. Rituximab plus peg-interferon alfa/ribavirin compared with peg-interferon alfa/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010; 116: 326-34.